Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rollover Study of Mitapivat
NCT05777993Phase 4Enrolling by invitation
- Sponsor
- Agios Pharmaceuticals
- Start
- Jul 2023
- Primary completion
- Aug 2029
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 4 trial of mitapivat in pyruvate kinase deficiency (PKD), Hemolytic anemia (HA), sickle cell disease (SCD), thalassemia, sponsored by Agios Pharmaceuticals. Started Jul 2023; status: enrolling by invitation.
02
Drugs
mitapivat
03
Conditions
pyruvate kinase deficiency (PKD)Hemolytic anemia (HA)sickle cell disease (SCD)thalassemia
Beyond the preview
Go deeper on NCT05777993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05777993.